Search Results - "Martin Lorente, Cristina"

Phase II clinical trial of PM00104 (Zalypsis®) in urothelial carcinoma patients progressing after first-line platinum-based regimen by Castellano, Daniel E., Bellmunt, Joaquim, Maroto, José Pablo, Font-Pous, Albert, Morales-Barrera, Rafael, Ghanem, Ismael, Suarez, Cristina, Martín Lorente, Cristina, Etxaniz, Olatz, Capdevila, Laia, Coronado, Cinthya, Alfaro, Vicente, Siguero, Mariano, Fernández-Teruel, Carlos, Carles, Joan

“…Purpose This exploratory phase II clinical trial evaluated the antitumor activity, safety profile and pharmacokinetics of PM00104 (Zalypsis ® ) 3 mg/m 2 1 h…”
Get full text

Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges by Rodríguez, Francisco, Caruana, Pablo, De la Fuente, Noa, Español, Pía, Gámez, María, Balart, Josep, Llurba, Elisa, Rovira, Ramón, Ruiz, Raúl, Martín-Lorente, Cristina, Corchero, José Luis, Céspedes, María Virtudes

“…Cancer is one of the main causes of death worldwide. To date, and despite the advances in conventional treatment options, therapy in cancer is still far from…”
Get full text

Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial by Pujade-Lauraine, Eric, Brown, Jessica, Barnicle, Alan, Wessen, Jonathan, Lao-Sirieix, Pierre, Criscione, Steven W, du Bois, Andreas, Lorusso, Domenica, Romero, Ignacio, Petru, Edgar, Yoshida, Hiroyuki, Vergote, Ignace, Colombo, Nicoletta, Hietanen, Sakari, Provansal, Magali, Schmalfeldt, Barbara, Pignata, Sandro, Martín Lorente, Cristina, Berton, Dominique, Runnebaum, Ingo B, Ray-Coquard, Isabelle

“…The PAOLA-1/ENGOT-ov25 trial of maintenance olaparib plus bevacizumab for newly diagnosed advanced high-grade ovarian cancer demonstrated a significant…”
Get more information

Management of advanced ovarian cancer in Spain: an expert Delphi consensus by Redondo, Andres, Oaknin, Ana, Rubio, Maria Jesus, Barretina-Ginesta, Maria-Pilar, de Juan, Ana, Manso, Luis, Romero, Ignacio, Martin-Lorente, Cristina, Poveda, Andres, Gonzalez-Martin, Antonio

“…To determine the state of current practice and to reach a consensus on recommendations for the management of advanced ovarian cancer using a Delphi survey with…”
Get full text

Treatment Patterns and Survival Outcomes Before and After Access to Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma: A Single-Center Retrospective Study From 2004 to 2021 by Tapia, Jose C., Bosma, Freya, Gavira, Javier, Sanchez, Sofia, Molina, Maria Alejandra, Sanz-Beltran, Judit, Martin-Lorente, Cristina, Anguera, Georgia, Maroto, Pablo

“…•Immune checkpoint inhibitors emerged as a the predominant 2L treatment, leading to a substantial decrease in the utilization of chemotherapies beyond the…”
Get full text

Cumulative incidences of hypogonadism, hypertension, and dyslipidaemia in patients with stage I seminoma treated with a risk-adapted strategy: a Spanish single-centre retrospective analysis by Tapia, Jose C., Gavira, Javier, Anguera, Georgia, Sanchez, Sofia, Romano, Alejandra, Bosma, Freya, Molina, Alejandra, Sanz-Beltran, Judit, Martin-Lorente, Cristina, Algaba, Fernando, Maroto, Pablo

“…Purpose To describe the incidences of hypogonadism, hypertension, and dyslipidaemia in patients with stage 1 seminoma (S1S) testicular cancer (TC) treated with…”
Get full text

Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial by Colombo, Nicoletta, Biagioli, Elena, Harano, Kenichi, Galli, Francesca, Hudson, Emma, Antill, Yoland, Choi, Chel Hun, Rabaglio, Manuela, Marth, Christian, Parma, Gabriella, Fariñas-Madrid, Lorena, Nishio, Shin, Allan, Karen, Lee, Yeh Chen, Piovano, Elisa, Pardo, Beatriz, Nakagawa, Satoshi, McQueen, John, Zamagni, Claudio, Manso, Luis, Takehara, Kazuhiro, Ferrero, Annamaria, Tognon, Germana, Lissoni, Andrea Alberto, Petrella, Mariacristina, Laudani, Maria Elena, Uggeri, Sara, Barretina Ginesta, M Pilar, Casanova, Claudia, Arcangeli, Valentina, Antonuzzo, Lorenzo, Gadducci, Angiolo, Cosio, Stefania, McNeish, Ian, Tookman, Laura, Redondo Sanchez, Andrés, Choi, Chel Hun, Baldini, Editta, Palaia, Innocenza, Benedetti Panici, Pierluigi, Takahashi, Nobutaka, Lombard, Janine, Ardizzoia, Antonio, Bologna, Alessandra, Herrero Ibáñez, Ana Maria, Musolino, Antonino, Márquez Vázquez, Raúl, Pietzner, Klaus, Braicu, Elena, Heinzelmann-Schwarz, Viola A., Powell, Melanie, Yokoyama, Yoshihito, Abeni, Chiara, Cueva, Juan Fernando, Trillsch, Fabian, Ataseven, Beyhan, Petru, Edgar, Heubner, MartinLeonhard, Sadozye, Azmat Hassanq, Dubey, Sidharth, Tiley, Susan, Chrystal, Kathryn, Kim, Sang Wun, Fehr, Mathias, Scatchard, Kate, Anand, Anjana, Taylor, Alexandra, Enomoto, Takayuki, Yoshihara, Kosuke, Selva-Nayagam, Sudarsha, Karki, Bhaskar, Wilkinson, Kate, Chantrill, Lorraine, Lee, Chulmin, Bertolini, Alessandro, Narducci, Filomena, Bellotti, Giovanna, Fusco, Vittorio, Aebi, Stefan, Del Grande, Maria, Tokunaga, Hideki, Shigeta, Shogo, Goss, Geraldine, Siow, Zhen Rong, Steer, Christopher, Lee, Kwang-Beom, Di Meglio, Giovanni, Massa, Elena, De Marino, Elvira, Tortora, Vincenzo, Palacio Vazquez, Isabel, Tsuji, Kosuke, Tominaga, Eiichiro, Black, Allison, So, Kyeong A, Suh, Dong Hoon, Lee, Keun Ho, Fossati, Roldano, Carlucci, Luciano, Barberis, Massimo

“…At the time of AtTEnd trial design, standard treatment for advanced or recurrent endometrial cancer included carboplatin and paclitaxel chemotherapy. This…”
Get full text

SEOM–GEICO clinical guideline on epithelial ovarian cancer (2023) by Perez-Fidalgo, Jose Alejandro, Gálvez-Montosa, Fernando, Guerra, Eva María, Madariaga, Ainhoa, Manzano, Aranzazu, Martin-Lorente, Cristina, Rubio-Pérez, Maria Jesús, Alarcón, Jesus, Barretina-Ginesta, María Pilar, Gaba, Lydia

“…In recent years, the incorporation of new strategies to the therapeutic armamentarium has completely changed the outcomes of epithelial ovarian cancer (EOC)…”
Get full text

Homologous recombination repair mutation gene panels (excluding BRCA) are not predictive of maintenance olaparib plus bevacizumab efficacy in the first-line PAOLA-1/ENGOT-ov25 trial by Pujade-Lauraine, Eric, Brown, Jessica, Barnicle, Alan, Rowe, Phil, Lao-Sirieix, Pierre, Criscione, Steven, du Bois, Andreas, Lorusso, Domenica, Romero, Ignacio, Petru, Edgar, Yoshida, Hiroyuki, Vergote, Ignace, Colombo, Nicoletta, Hietanen, Sakari, Provansal, Magali, Schmalfeldt, Barbara, Pignata, Sandro, Martin-Lorente, Cristina, Berton, Dominique, Runnebaum, Ingo, Ray-Coquard, Isabelle

“…In the Phase III PAOLA-1/ENGOT-ov25 (NCT02477644) trial, the addition of the PARP inhibitor olaparib to bevacizumab maintenance therapy led to a significant…”
Get full text

Comparative benchmarking of regulatory drug approvals by Food & Drug Administration (FDA): A cross disease comparison with gynecologic malignancies by Rodriguez-Freixinos, Victor, Wilson, Michelle K., Lheureux, Stephanie, Martin-Lorente, Cristina, Karakasis, Katherine, Wang, Lisa, Panzarella, Tony, Oza, Amit M.

“…Abstract only…”
Get full text

Correlation between immune-related adverse events (irAEs) and efficacy in patients with solid tumors treated with immune-checkpoints inhibitors (ICIs) by Riudavets, Mariona, Barba, Andrés, Maroto, Pablo, SULLIVAN, IVANA GABRIELA, Anguera, Georgia, Páez, David, del Carpio, Luis, Callejo, Ana, Gonzalez Blanco, Cintia, Garcia Planellas, Esther, Castillo, Diego, Facundo, Carme, Genua, Idoia, Martin Lorente, Cristina, Virgili, Ana, Sebio, Ana, Gallego, Oscar, Lopez-Pousa, Antonio, Barnadas, Agust, Majem, Margarita

“…Abstract only…”
Get full text

An analysis of malignant bowel obstruction (MBO) outcomes in patients with epithelial ovarian carcinoma (EOC) by Martin Lorente, Cristina, Mackay, Helen, Laframboise, Stephane, O'Brien, Catherine, Butler, Marcus O., Dhani, Neesha C., Wilson, Michelle K., Lheureux, Stephanie, Rodriguez-Freixinos, Victor, Rosen, Barry, Murphy, Joan, Ferguson, Sarah E, Bernardini, Marcus, Dodge, Jason, Lau, Anthea, Wang, Lisa, Oza, Amit M.

“…Abstract only…”
Get full text

P53 functional mutation type in high-grade serous ovarian cancer and clinical outcomes by Mandilaras, Victoria, Garg, Swati, Burnier, Julia, Karakasis, Katherine, Wang, Lisa, Mackay, Helen, Dhani, Neesha C., Butler, Marcus O., Rodriguez-Freixinos, Victor, Wilson, Michelle K., Martin-Lorente, Cristina, Ethier, Josee-Lyne, Bedard, Philippe L., Siu, Lillian L., Clarke, Blaise, Shaw, Patricia Ann, Stockley, Tracy, Oza, Amit M., Lheureux, Stephanie

“…Abstract only…”
Get full text

Castrate-resistant prostate cancer (CRPC): Prognostic and predictive value of testosterone levels in patients receiving chemotherapy by Gomez De Liano Lista, Alfonso, Reig, Óscar, Mellado, Begoña, Martin Lorente, Cristina, Cillan, Elena, Macias, Ismael, Sancho, Gemma, Palou, Joan, Maroto-Rey, Pablo

“…Abstract only e16049 Background: Recent development of new second line therapies in patients with CRPC upon progression to docetaxel has raised the question of…”
Get full text

Phase II study of XL184 (cabozantinib) in recurrent or metastatic endometrial cancer: A trial of the PMH, Chicago, and California Phase II Consortia by Wilson, Michelle, Dhani, Neesha C., Hirte, Hal W., Welch, Stephen, Steed, Helen, Martin, Lainie P., Lheureux, Stephanie, Martin-Lorente, Cristina, Mackay, Helen, Butler, Marcus O., Wang, Lisa, Quintos, Judy, Allen, Katie, Roman, Lynda, Wright, John Joseph, Oza, Amit M.

“…Abstract only…”
Get full text

Phase II study of oral ENMD-2076 administered to patients with ovarian clear cell carcinoma: A trial of the Princess Margaret Phase II Consortium by Martin-Lorente, Cristina, Tan, David SP, Dhani, Neesha, Butler, Marcus, Mackay, Helen, Wilson, Michelle, Lheureux, Stephanie, Hirte, Hal W., Welch, Stephen, Weberpals, Johanne Ingrid, Prafullg, Ghatage, Tonkin, Katia, Wang, Lisa, Haley, Anna, Capobianco, Stephanie, Oza, Amit M.

“…Abstract only…”
Get full text

A phase 1/2 study of ipilimumab in women with metastatic or recurrent HPV-related cervical carcinoma: A study of the Princess Margaret and Chicago N01 Consortia by Lheureux, Stephanie, Butler, Marcus O., Fleming, Gini F., Hirte, Hal W., Cristea, Mihaela C., Ghatage, Prafull, Martin, Lainie P., Mackay, Helen, Dhani, Neesha C., Wilson, Michelle, Martin-Lorente, Cristina, Quintos, Judy, Wang, Lisa, Udagani, Smitha, Oza, Amit M.

“…Abstract only…”
Get full text

A randomized, placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with AZD 1775 (MK 1775) in women with recurrent, platinum-resistant epithelial ovarian, primary peritoneal, or Fallopian tube cancers: Trial of Princess Margaret, Mayo, Chicago, and California consortia by Lheureux, Stephanie, Weberpals, Johanne Ingrid, Wahner Hendrickson, Andrea Elisabeth, Fleming, Gini F., Olawaiye, Alexander, Brana, Irene, Mackay, Helen, Dhani, Neesha C., Wilson, Michelle K., Rodriguez-Freixinos, Victor, Martin-Lorente, Cristina, Ward, Jacklyn, Chang, Karen, Wang, Lisa, Speers, Vanessa, Karakasis, Katherine, Bowering, Valerie Lydia, Chen, Alice, Brenton, James, Oza, Amit M.

“…Abstract only…”
Get full text

Molecular profiling and targeted therapy in advanced endometrial cancer by Wilson, Michelle K., Bedard, Philippe L., Joshua, Anthony M., Mackay, Helen, Butler, Marcus O., Dhani, Neesha C., Lheureux, Stephanie, Martin-Lorente, Cristina, Rodriguez-Freixinos, Victor, Clarke, Blaise, Shaw, Patricia, Milea, Anca, Wang, Lisa, Kamel-Reid, Suzanne, Stockley, Tracy, Bruce, Jeff, Pugh, Trevor John, Oza, Amit M.

“…Abstract only…”
Get full text

Testosterone levels as a prognostic factor for survival in patients with castrate-restistant prostate cancer (CRPC) by Gomez de Liaño, Alfonso, Maroto, José Pablo, Martin Lorente, Cristina, Cillan, Elena, Macias, Ismael, Stradella, Agostina, Sullivan, Ivana, Murata, Paola, Arqueros, Cristina, Anguera, Georgia, Condori, Dhiossett, Barnadas, Agust

“…Abstract only e15159 Background: To analyze the prognostic value for survival of the absolute levels of serum testosterone in patients under the definition of…”
Get full text